These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15060427)

  • 1. A rapid microtitre plate screening method for in vitro assessment of fibrinolysis: a preliminary report.
    Paul-Brent PA; Cattley TN; Myers SP; Brooks L; Cheras PA
    Blood Coagul Fibrinolysis; 2004 Apr; 15(3):273-8. PubMed ID: 15060427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision.
    Jespersen J; Astrup T
    Haemostasis; 1983; 13(5):301-15. PubMed ID: 6360818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new euglobulin clot lysis assay for global fibrinolysis.
    Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
    Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis.
    Nordby E; Arnesen H; Andersen P; Godal HC
    Scand J Haematol; 1980 Nov; 25(5):407-11. PubMed ID: 7221476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of euglobulin clot lysis time as a screening method for determination of blood plasma fibrinolytic activity after venous occlusion.
    Boberg M; Killander A
    Acta Med Scand; 1983; 213(4):309-11. PubMed ID: 6613690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of five streptokinase formulations using the euglobulin lysis test and the plasminogen activation assay.
    Couto LT; Donato JL; de Nucci G
    Braz J Med Biol Res; 2004 Dec; 37(12):1889-94. PubMed ID: 15558196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
    Jones AJ; Meunier AM
    Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Streptokinase: correlation between different methods of biological evaluation].
    Oliva LM; Guagliardo MV; Albertengo ME
    Sangre (Barc); 1998 Jun; 43(3):231-5. PubMed ID: 9741232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACTIVATION OF THE FIBRINOLYTIC SYSTEM IN HUMAN BLOOD BY STREPTOKINASE AND CHANGES IN THIS SYSTEM AND IN THE EUGLOBULIN CLOT LYSIS TIME IN RELATION TO AGE AND SEX.
    KONTTINEN YP
    Scand J Clin Lab Invest; 1965; 17():SUPPL 82:1-111. PubMed ID: 14320094
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolysis in the pigeon (Columba livia).
    Ahmad N; Dube B; Agarwal GP; Dube R
    Thromb Haemost; 1979 Oct; 42(3):955-8. PubMed ID: 505408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time.
    Boudjeltia KZ; Cauchie P; Remacle C; Guillaume M; Brohée D; Hubert JL; Vanhaeverbeek M
    BMC Biotechnol; 2002 May; 2():8. PubMed ID: 11985782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 125I-fibrinogen euglobulin clot-lysis test.
    Horvath AE; Gralnick HR
    Am J Clin Pathol; 1978 Aug; 70(2):271-4. PubMed ID: 696685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-automatic method for routine evaluation of fibrinolytic components.
    Collen D; Tytgat G; Verstraete M
    J Clin Pathol; 1968 Nov; 21(6):705-7. PubMed ID: 4237924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase).
    Musselman DR; Tate DA; Oberhardt BJ; Abruzzini AF; Blauwet MB; Koch G; Dehmer GJ
    Am J Cardiol; 1994 Mar; 73(8):544-9. PubMed ID: 8147298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [On the difference between serum and euglobulin in determination of fibrinolytic activities by streptokinase-activated method with special reference to the relationship with antiplasmin agents].
    Miyatani K; Fukui I
    Rinsho Byori; 1971 Mar; 19(3):223-6. PubMed ID: 4252723
    [No Abstract]   [Full Text] [Related]  

  • 18. Euglobulin lysis times: an update.
    Glassman A; Abram M; Baxter G; Swett A
    Ann Clin Lab Sci; 1993; 23(5):329-32. PubMed ID: 8239479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
    Kostka B; Para J; Sikora J
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
    Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
    Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.